

Left Atrial Appendage Occlusion versus Novel Oral Anticoagulation for Stroke Prevention in Atrial Fibrillation – One Year Survival

Tiosano et al.

Supplementary material

Contents

| | |
|---|---|
| Table S1 – Baseline characteristics of study participants with CrCl ≤ 60 mL/min | 2 |
| Table S2 – The association between LAAO vs. NOACs and 1-year mortality – stratification by distinct groups. | 3 |

Table S1 – Baseline characteristics of study participants with CrCl ≤ 60 mL/min

| | LAAO N=62 | NOACs N=217 | P |
|---|---------------------|-----------------------|----------|
| Age | 79.0±7.97 | 79.5±11.5 | 0.736 |
| Sex: Male | 31 (50.0%) | 121 (55.8%) | 0.510 |
| Hypertension | 50 (80.6%) | 172 (79.3%) | 0.953 |
| Diabetes Mellitus | 26 (41.9%) | 81 (37.3%) | 0.610 |
| Ischemic Heart Disease | 36 (58.1%) | 108 (49.8%) | 0.313 |
| Congestive Heart Failure | 25 (40.3%) | 86 (39.6%) | 1.000 |
| Ejection fraction (%) | 52.8±7.69 | 52.6±11.1 | 0.873 |
| Prior bleeding | 46 (74.2%) | 168 (77.4%) | 0.719 |
| Prior stroke or TIA | 31 (50.0%) | 85 (39.2%) | 0.168 |
| CrCl | 35.8±20.0 | 37.3±17.0 | 0.610 |
| CHA₂DS₂-VASc | 4.39±1.51 | 4.16±1.64 | 0.310 |
| CHA₂DS₂-VASc => 4 | 47 (75.8%) | 157 (72.4%) | 0.705 |
| HAS-BLED | 4.13±1.18 | 4.38±1.27 | 0.153 |
| HAS-BLED => 4 | 45 (72.6%) | 185 (85.3%) | 0.034 |
| Prior Aspirin treatment | 23 (37.1%) | 74 (34.1%) | 0.775 |

LAAO: Left Atrial Appendage Occlusion; NOACs: Novel Oral Anticoagulants; TIA: Transient Ischemic Attack; CrCl: Creatinine Clearance, mL/min

Table S2 – The association between LAAO vs. NOACs and 1-year mortality – stratification by distinct groups.

| | LAAO | NOACs |
|----------------------|----------------|--------------|
| Under age 80 | 6/174 (3.45%) | 2/62 (3.23%) |
| Age 80 plus | 26/168 (15.5%) | 3/52 (5.77%) |
| Males | 14/202 (6.93%) | 4/70 (5.71%) |
| Females | 18/140 (12.9%) | 1/44 (2.27%) |
| CrCl 60 plus | 3/125 (2.40%) | 3/52 (5.77%) |
| CrCl under 60 | 29/217 (13.4%) | 2/62 (3.23%) |

LAAO: Left Atrial Appendage Occlusion; NOACs: Novel Oral Anticoagulants; CrCl: Creatinine Clearance